Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Summary

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

Timeline

Start

2023-06-16

Primary completion

2025-03-04

Completion

2025-03-28

Publications

• Lizama BN, Reaver A, Look G, Caggiano AO, Hamby ME. Sigma-2 receptor modulators alter low-density lipoprotein receptor-mediated lipid uptake in retinal pigment epithelial cells. Exp Eye Res. 2026 Jun;267:110944. doi: 10.1016/j.exer.2026.110944. Epub 2026 Feb 24.

Drugs

Indications